LRRK2 Cohort Consortium
The MJFF-led LRRK2 Cohort Consortium brought research groups together — sharing resources and troubleshooting common problems — to speed efforts to move LRRK2 toward therapeutic relevance for patients.
The Consortium comprised three initiatives:
Each cohort includes LRRK2-positive Parkinson’s patients, unaffected LRRK2 mutation carriers, idiopathic PD patients and control subjects. The Consortium contributed a common core dataset and clinical data and biological samples are stored in a comprehensive Parkinson's database and biorepository.
Available Biospecimens and Data
MJFF makes data and biosamples available to the scientific community to conduct research on novel PD biomarkers. Biospecimens and data from the LRRK2 Cohort Consortium (LCC) are available to qualified members of the research community.
To apply for access to data from the LCC, you may submit a request here. LCC samples are available through a collaborative resource access program with the National Institute for Neurological Disorders and Stroke (NINDS). To learn more about requesting LCC samples and funding, please visit our Access Data and Biospecimens page.
LRRK2 Cohort Consortium Publications
Analysis from the LRRK2 Cohort Consortium has yielded notable findings. Researchers are preparing these papers for publication.
|Paper||Writing Committee Lead||Writing Committee Members||Status|
|Difference between iPD-LRRK2 PD||Connie Marras, MD, PhD||Alcalay, Duda, Fernandez, Ruiz, Saunders-Pullman, Tolosa, Waro||In Preparation|
|Premotor LRRK2 Characterization||Eduardo Tolosa, MD, PhD||Alcalay, Duda, Marras, Mondragon, Saunders-Pullman, Waro||In Preparation|
View a list of all publications and presentations from projects utilizing the resources.
Ongoing Research Utilizing LRRK2 Cohort Consortium Specimens
The following research studies are actively accessing LRRK2 Cohort Consortium samples. Researchers may apply to use biospecimens through the Access to Data and Biospecimens page.
|Project Title||Principal Investigator||Institution||Specimen(s) Used|
|Influence of Immune Subtypes on the LRRK2 Phenotype||Daniela Berg, MD||Centre of Neurology and Hertie-Institute for Clinical Brain Research, University Hospital Tuebingen||Plasma|
|Alpha-synuclein and other biomarkers in biological samples of LRRK2 PD||Eduardo Tolosa, MD, PhD||Hospital Clinic Universitari de Barcelona||CSF|
|Effect of LRRK2 mutations on PD-associated inflammation||Nicolas Dzamko, PhD||Neuroscience Research Australia||CSF, serum|
|aSyn 3’UTR modulation in LRRK2 carriers as a potential biomarker||Asa Abeliovich, MD, PhD||Columbia University Medical Center||RNA|
|LRRK2 in urine as a biomarker for PD||Andrew West, PhD||University of Alabama, Birmingham||Urine|
|Purine biomarkers of LRRK2 PD||Michael Schwarzschild, MD, PhD||Mass General Institute for Neurodegenerative Disease||Plasma|